News Archive // Chi-Med

Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models

R&D Briefing for Investors 2017

2016 Full Year Financial Results

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors

ASCO GU 2017: Savolitinib Phase II in advanced papillary renal cell cancer

Oncotarget: Sulfatinib Phase I Results

ASCO GI 2017: Fruquintinib in Combination with Paclitaxel in 2L Gastric Cancer

Journal of Hematology & Oncology: fruquintinib Phase Ib & Phase II in colorectal cancer

WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC

ASH 2016: Syk Inhibitor HMPL-523 Anti-tumor Activity in vitro and in vivo

WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis

ACR 2016: Phase I Dose Escalating Study of HMPL-523 in Australian Male Healthy Subjects

CLSA Investors' Forum

2016 Half-Year Financial Results

ASCO 2016: Safety profile and preliminary clinical efficacy of epitinib in EGFRm+ NSCLC

ASCO 2016: Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer

AACR 2016: Activity of Savolitinib against MET Ex14 mutations and resistance to METi through decoupling from MYC expression

2015 Full Year Results Presentation

EORTC 2015: Synergistic effect of c-Met inhibitor Savolitinib in combination with a VEGFR inhibitor Fruquintinib in clear cell renal cell carcinoma xenograft models

EORTC 2015: First-in-human phase I study of selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

ESMO 2015: Phase II trial of fruquintinib in metastatic colorectal cancer

2015 Interim Results Presentation

2015 Deutsche Bank Healthcare Conference (Boston)

ASCO 2015: Preliminary results of TATTON, a multi-arm Phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 (savolitinib) or selumetinib in EGFR-mutant lung cancer

Overview of Chi-Med

2014 Full Year Results Presentation

2015 JP Morgan Healthcare Conference (San Francisco)

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy (Cancer Biology & Therapy 2014)

ACR/ARHP 2014: HM-0523 (HMPL-523), a novel Syk inhibitor, blocks glomerulonephritis and extends life spans in lupus prone MRL/lpr mice

2014 R&D Briefing

Discovery of [savolitinib] as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer (Journal of Medicinal Chemistry 2014)

2014 Interim Results Presentation

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors

AACR 2014: Anti-tumour activity of Epitinib in patient derived esophagus cancer models

AACR 2014: Discovery and Early Development of HMPL-504 (savolitinib)

AACR 2014: Targeting MET in preclinical models to support the clinical development of AZD6094/HMPL-504 (savolitinib) in NSCLC

2013 Full Year Results Presentation

ACR 2013: HMPL-523, a novel Syk inhibitor, significantly ameliorates the severity of arthritis in rodents

2013 R&D Briefing

2013 Interim Results Presentation

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors

AACR 2013: Preclinical disposition and pharmacokinetics of savolitinib, a novel selective cMet inhibitor

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer

2012 Full Year Results Presentation

HMPL-004 (Andrographis paniculata extract) Prevents Development of Murine Colitis by Inhibiting T-cell Proliferation and TH1/TH17 Responses (Inflammatory Bowel Diseases 2013)

Chi-Med/Nestlé Health Science Analyst Conference Call Transcript